

For Further Information Contact:

Roy Wolvin
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com

For Immediate Release:

Journal of Clinical Laboratory Analysis Publishes Positive New Data Bolstering Nymox's AlzheimerAlert™ Urine Test for Alzheimer's Disease

HASBROUCK HEIGHTS, NJ (January 25, 2007) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce the publication of a new peer-reviewed report in the most recent issue of the *Journal of Clinical Laboratory Analysis* providing further positive data on the accuracy and utility of the Company's urinary AlzheimerAlert™ test (*J Clin Lab Anal.* Jan 2007;21:24-33, "Competitive ELISA studies of neural thread protein in urine in Alzheimer's disease"). The paper reports excellent performance in laboratory studies and impressive reproducibility of clinical test results for patients and controls who were re-tested at intervals ranging from 2 days to 4.5 years.

Earlier this month, the successful results of a multi-center double blind independent clinical study of the Company's urinary AlzheimerAlert™ test were published in the most recent issue of the *Journal of the American Medical Directors Association* (*J Am Med Dir Assoc.* Jan 2007; 8:21-30; "A multi-center blinded prospective study of urine neural thread protein measurements in patients with suspected Alzheimer's disease," Goodman I et al.). The newly published independent peer-review study from 8 prestigious centers across the U.S. found the level of accuracy of the AlzheimerAlert™ urine test to be over 90%. The study was double-blind and involved expert assessments and state-of-the-art clinical correlations and continued evaluations.

AlzheimerAlert™ is Nymox's proprietary urine based diagnostic aid for Alzheimer's disease. It is the only proven accurate non-invasive AD test technology available. The test has the CE Mark, allowing it to be marketed in Europe, and is also available to physicians in the U.S. through the Company's national CLIA-certified Clinical Reference Laboratory in New Jersey at a cost of \$295. Nymox currently has numerous initiatives underway for the AlzheimerAlert™ testing technology, including marketing and distribution overseas, and global product development.

There are an estimated 4.5 million people with Alzheimer's disease in the United States alone; by 2050 this number is projected to increase almost three times to 13.2 million. Worldwide estimates of the current number of people with Alzheimer's disease range from 15 to 20 million. The annual national direct and indirect costs of caring for Alzheimer patients in the U.S. alone are estimated at \$100 billion. The human toll on patients, families and caregivers is incalculable.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain “forward-looking statements” as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management’s current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox’s filings with the United States Securities and Exchange Commission and other regulatory authorities.